Growth Metrics

Eli Lilly (LLY) Total Current Liabilities (2016 - 2026)

Eli Lilly filings provide 18 years of Total Current Liabilities readings, the most recent being $36.6 billion for Q1 2026.

  • On a quarterly basis, Total Current Liabilities rose 21.84% to $36.6 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $36.6 billion, a 21.84% increase, with the full-year FY2025 number at $35.2 billion, up 24.15% from a year prior.
  • Total Current Liabilities hit $36.6 billion in Q1 2026 for Eli Lilly, up from $35.2 billion in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $40.1 billion in Q3 2025 to a low of $13.4 billion in Q1 2022.
  • Median Total Current Liabilities over the past 5 years was $24.7 billion (2024), compared with a mean of $25.1 billion.
  • Biggest five-year swings in Total Current Liabilities: rose 3.49% in 2022 and later soared 62.68% in 2025.
  • Eli Lilly's Total Current Liabilities stood at $17.1 billion in 2022, then soared by 59.25% to $27.3 billion in 2023, then increased by 3.97% to $28.4 billion in 2024, then increased by 24.15% to $35.2 billion in 2025, then increased by 3.99% to $36.6 billion in 2026.
  • The last three reported values for Total Current Liabilities were $36.6 billion (Q1 2026), $35.2 billion (Q4 2025), and $40.1 billion (Q3 2025) per Business Quant data.